3.4.21.109: matriptase
This is an abbreviated version!
For detailed information about matriptase, go to the full flat file.
Word Map on EC 3.4.21.109
-
3.4.21.109
-
hepatocyte
-
hepcidin
-
hai-1
-
anemia
-
metastasis
-
prostate
-
hepsin
-
zymogen
-
transferrin
-
prostasin
-
overload
-
trypsin-like
-
irida
-
plasminogen
-
hemojuvelin
-
iron-refractory
-
kunitz-type
-
inhibitor-1
-
kunitz
-
ttsps
-
hemochromatosis
-
erythropoiesis
-
microcytic
-
membrane-anchored
-
urokinase-type
-
ferroportin
-
iron-deficiency
-
pro-hgf
-
pericellular
-
upa
-
autoactivation
-
two-chain
-
hypochromic
-
medicine
-
protease-activated
-
tmprss4
-
spint2
-
corpuscular
-
erythroferrone
-
profilaggrin
-
camostat
-
corin
-
epithelial-derived
-
par-2
-
hypotrichosis
-
drug development
-
diagnostics
- 3.4.21.109
- hepatocyte
- hepcidin
- hai-1
- anemia
- metastasis
- prostate
- hepsin
- zymogen
- transferrin
- prostasin
- overload
-
trypsin-like
-
irida
- plasminogen
- hemojuvelin
-
iron-refractory
-
kunitz-type
- inhibitor-1
-
kunitz
-
ttsps
- hemochromatosis
-
erythropoiesis
-
microcytic
-
membrane-anchored
-
urokinase-type
-
ferroportin
-
iron-deficiency
- pro-hgf
-
pericellular
- upa
-
autoactivation
-
two-chain
-
hypochromic
- medicine
-
protease-activated
-
tmprss4
-
spint2
-
corpuscular
-
erythroferrone
- profilaggrin
- camostat
- corin
-
epithelial-derived
- par-2
- hypotrichosis
- drug development
- diagnostics
Reaction
cleaves various synthetic substrates with Arg or Lys at the P1 position and prefers small side-chain amino acids, such as Ala and Gly, at the P2 position =
Synonyms
Epi/MTP, epithin, epithin/matriptase, influenza virus-activating protease, matriptase, matriptase-1, matriptase-2, matriptase-3, matriptase1, matriptase1a, membrane-type serine protease 1, membrane-type serine protease 1/matripase, membrane-type serine protease-1, membrane-type serine protease1, membrane-type serine proteinase matripase, membrane-type serine proteinase matriptase, More, MT-2, MT-SP-1, MT-SP1, MT-SP1/matripase, MT2, notopleural, prostamin, PRSS14, r-matripase, serine protease matriptase-2, serine protease SNC19/matripase, SNC19, ST-14, ST14, suppression of tumorigenecity 14, suppressor of tumorigenicity 14, suppressor of tumorigenicity 14 protein, suppressor of tumorigenicity-14, TADG-15, TADG15, TMPRSS6, transmembrane serine protease 6, tumor-associated differentially expressed gene-15, tumor-associated type II transmembrane serine protease, type 2 transmembrane serine protease, type II transmembrane protease, type II transmembrane serine protease
ECTree
3.4.21.109 matriptaseAdvanced search results
results (
results (Molecular Weight
Molecular Weight on EC 3.4.21.109 - matriptase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
MOLECULAR WEIGHT 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
100000
-
immunoblotting, matripase-hepatocyte growth factor activator inhibitor-1 complex
110
-
Western blot analysis using seminal fluid, seminal fluid contains only activated matriptase in complex with antithrombin III, supposed 70 kDa active matriptase and a 40 kDa antithrombin III-fragment
110000
120000
130000
-
SDS-PAGE and Western blot, reducing conditions, matriptase-hepatcyte growth factor activator inhibitor-1 complex
25000
serine protease domain, identified by SDS-PAGE, Western blot analysis and LC-MS,MS, without serpin complex
28000
29000
30000
32000
-
SDS-PAGE reducing and non-reducing conditions and Western blot using anti-rat matriptase catalytic domain anibody, designated pseudozymogen His6t-S-CD consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase, before cleavage with enterokinase
33000
35000
-
catalytic domain, Asp603 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
40000
-
catalytic domain, Asp603 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
43000
-
under non-reducing conditions in a sample of medium three bands 61 kDa, 55 kDa, 43 kDa are visible using Western blotting with a anti-myc antibody
45000
noncatalytic domain, identified by SDS-PAGE, Western blot analysis and LC-MS,MS
55000
-
under non-reducing conditions in a sample of medium three bands 61 kDa, 55 kDa, 43 kDa are visible using Western blotting with a anti-myc antibody
60000
-
serine protease domain, dimer, determined by SDS-PAGE and Western blot analysis
61000
-
under non-reducing conditions in a sample of medium three bands 61 kDa, 55 kDa, 43 kDa are visible using Western blotting with a anti-myc antibody
70000
75000
80000
85000
90000
93000
95000
110000
-
gelatin zymography or immunoblotting, matripase/hepatocyte growth factor activator inhibitor complex
120000
-
immunoblotting, 70000 active matripase plus full-length hepatocyte growth factor activator inhibitor-1
120000
-
SDS-PAGE, reducing condition, and Western blot, activated form of matriptase in complex with hepatocyte growth factor activator inhibitor 1
120000
-
x * 95000, single-chain latent enzyme, SDS-PAGE, x * 120000, active enzyme in complex with inhibitor HAI-1, SDS-PAGE
28000
-
catalytic domain, Asp603 - Val855, after treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
28000
-
extracellular domains, Tyr81 - Val855, after treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
28000
-
SDS-PAGE and Western blot analysis, reducing conditions, activated matriptase, disulfide-linked two-chain C-terminal fragment
28000
-
SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, activated C-terminal part consiting of the catalytic domain
28000
-
SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, activated form of matriptase
28000
-
Western blot analysis using conditioned medium, catalytic domain of proteolytically active two-chain matriptase C-terminal fragment
30000
-
catalytic domain, Asp603 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
30000
-
serine protease domain, determined by SDS-PAGE and Western blot analysis
30000
-
SDS-PAGE reducing conditions and Western blot using anti-rat matriptase catalytic domain anibody, designated pseudozymogen His6t-S-CD consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase, after cleavage with enterokinase
30000
-
x * 70000, matriptase zymogen, SDS-PAGE, x * 30000, matriptase serine protease domain, SDS-PAGE
33000
-
SDS-PAGE and Western blot, reducing conditions, proteolytically active, disulfide two-chain matriptase C-terminal fragment found in both the apical and basolateral media of stably transfected Madin-Darby canine kidney cells
33000
-
SDS-PAGE, reducing condition, protease inhibitor cocktail, Western blotting using an anti-myc antibody in a sample of medium, two bands 93 kDa and 33 kDa are visible, 33 kDa fragment is a cleavage product of the carboxyl-terminal part
70000
-
SDS-PAGE, reducing condition, and Western blot, latent form of matriptase
70000
-
x * 70000, matriptase zymogen, SDS-PAGE, x * 30000, matriptase serine protease domain, SDS-PAGE
80000
serine protease domain, identified by SDS-PAGE, Western blot analysis and LC-MS,MS, including serpin complex
80000
-
x * 95000, full-length transmembrane isoform, SDS-PAGE, x * 80000, Gly149-early processed isoform, SDS-PAGE, x * 26000-29000, activated recombinant truncated wild-type catalytic domain, SDS-PAGE
85000
-
immunoblotting, full-length hepatocyte growth factor activator inhibitor-1 complexed with the serine protease domain of matripase
85000
-
SDS-PAGE and Western blot, reducing conditions, cleaved form of the enzyme
85000
-
Western blot analysis using seminal fluid, seminal fluid contains only activated matriptase in complex with hepatocyte growth factor activator inhibitor-1 (HAI-1), supposed 70 kDa active matriptase and a 15 kDa HAI-fragment
90000
-
Western blot analysis, post-translational processed enzyme, cleavage between Gly149 and Ser150 within the SEA domain
90000
-
SDS-PAGE and Western blot analysis, reducing conditions, non-activated enzyme, single-chain C-terminal fragment
90000
-
SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, non-activated C-terminal part
90000
-
SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, non-activated form of matriptase
90000
-
Western blot analysis using conditioned medium, proteolytically inactive single-chain C-terminal fragment
93000
-
SDS-PAGE and Western blot, reducing conditions, proteolytically inactive, single-chain matriptase C-terminal fragment found in both the apical and basolateral media of stably transfected Madin-Darby canine kidney cells
93000
-
SDS-PAGE, reducing condition, protease inhibitor cocktail, Western blotting using an anti-myc antibody in a sample of medium, two bands 93 kDa and 33 kDa are visible. 93 kDa fragment represents released single-chain carboxyl-terminal part
95000
complex can be converted by boiling to matriptase plus a 40000 Da protein doublet
95000
-
gelatin zymography or immunoblotting, matripase/hepatocyte growth factor activator inhibitor complex
95000
-
extracellular domains, Tyr81 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
95000
-
Western blot analysis using seminal fluid or urine, seminal fluid or urine contain only activated matriptase in complex with hepatocyte growth factor activator inhibitor-1 (HAI-1), supposed 70 kDa active matriptase and a 25 kDa HAI-fragment
95000
-
x * 95000, full-length transmembrane isoform, SDS-PAGE, x * 80000, Gly149-early processed isoform, SDS-PAGE, x * 26000-29000, activated recombinant truncated wild-type catalytic domain, SDS-PAGE
95000
-
x * 95000, single-chain latent enzyme, SDS-PAGE, x * 120000, active enzyme in complex with inhibitor HAI-1, SDS-PAGE
